Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-hydroxybutyrate
- Development stage
- Preclinical
- Lead developer
- Ketone Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Beta-hydroxybutyrate is a small molecule endogenous ketone body produced in the liver from fatty acids during periods of low carbohydrate intake (such as fasting or ketogenic diets). It serves as an alternative energy source for peripheral tissues when glucose is scarce. Beyond its metabolic role as an energy carrier (converted to acetyl-CoA and then ATP), it also acts as a signaling molecule with effects on gene expression (notably via histone deacetylase inhibition), lipid metabolism, neuronal function (including upregulation of brain-derived neurotrophic factor), and inflammation suppression through NLRP3 inflammasome inhibition. Beta-hydroxybutyrate is being investigated in clinical trials for conditions such as Crohn's disease, type 1 diabetes, type 2 diabetes, COVID-19 infection risk reduction and has been studied for potential benefits in neurological diseases like epilepsy and Alzheimer's disease[1][2][3][5][6].
- Brand names
- DeltaGKetoCaNaKetoForce
- Other names
- beta-hydroxybutyrateBHBbeta-hydroxybutyric acidβ-hydroxybutyric acidβ-OHB
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on beta-hydroxybutyrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-hydroxybutyrate.